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ABSTRACT 
The present work was designed to develop and compare orally inhalable sustained release formulation for salbutamol 
sulphate (SS), ambroxol hydrochloride (AH) and montelukast sodium (MS).  The emulsion solvent evaporation method was 
used to prepare microparticles with the polymers. The prepared polymer encapsulated microparticles were blended with 
carrier inhalable lactose and filled in size 3 hard empty gelatin capsule. Formulations T1-T9 were prepared with 1:1 ratio of 
PLGA (50:50), PLGA (75:25) and Eudragit RS100. The formulation T1 prepared with SS:PLGA (50:50) produces best result 
when compared with other formulations T2-T9.  Formulation T1 gives in vitro release 91.23% at 12 h and having particle 
size of microparticles (D0.5 µm) 1.94±0.6  and respiratory fraction 34.9 ± 2.59 %.  
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1. INTRODUCTION 
Today drugs were delivered through dry powder inhalers to treat respiratory diseases. The purpose of dry powder 
inhaler is to accumulate prescribed dose of powder aerosol into the air inhaled by patient in single large breath. During 
inhalation the powder particles were picked up and then broken up. Depending upon the size, particle will get deposited in 
different regions of respiratory tract during inhalation and releases drug to produce drug action.
 
SS, AH, MS were very 
suitable for sustained release formulations [1-3]. Many research work were carried out with these drugs but orally inhalable 
sustained release formulation is new concept [4]. The drugs SS, AH, MS versus polymers PLGA (50:50), PLGA (75:25) and 
Eudragit RS100 in the ratio 1:1, which were kept constant to prepare microparticles for orally inhalable sustained release 
dry powder for effective treatment of respiratory diseases [5-7]. The emulsion solvent evaporation method is most influential 
for the production of microparticles [8-9].  
2. EXPERIMENTAL SETUP 
 SS and AH was obtained as gift sample from Fourrts (India) Laboratories Ltd, Chennai. MS was obtained as gift 
sample from Orchid healthcare, Chennai. Poly (lactic-co-glycolic) acid (PLGA 75:25), Poly (lactic-co-glycolic) acid (PLGA 
50:50) was obtained from Brimingham polymer Inc, USA. Eudragit RL100 and Eudragit RS 100 were obtained as gift from 
Evonik India Pvt. Ltd., Mumbai. Polyvinyl alcohol, HPMC, PVP K90 were obtained from Orchid Healthcare, Chennai. 
Lactohale LH100 was obtained as gift sample from DMV, Netherlands, Dichloromethane, methanol and acetonitrile was 
obtained from Qualigens, Mumbai and potassium dihydrogen orthophosphate, sodium chloride and sodium hydroxide were 
obtained from SD fine chemicals, Mumbai, India. MTT Reagent (Weigh 5mg of MTT in sterile condition and packed in 4ml 
amber bottle), Dulbecco’s Modified Eagle’s Medium (DMEM) media, Dimethyl sulphoxide (DMSO) Co2
 
Incubator, ELISA 
Plate used in Orange Progene Pvt Ltd., Chennai. 
2.1 Drug encapsulation: 
  The microparticles were prepared by emulsion solvent evaporation method with some modifications. This 
method involves preparation of o/w emulsion between organic phase (OP) consisting of SS, AH and MS and polymers in 
methanol and aqueous phase (AP) containing 2% w/v PVA [10-15]. Drugs and polymers were dissolve in methanol by 
sonication, using vibracel sonicator. For drug encapsulation, the organic phase was emulsified in aqueous phase by 
homogenization at 10000rpm for 10 minutes using a probe homogenizer. The emulsion obtained was stirred overnight (15 
h) at 25±2⁰C using magnetic stirrer to ensure complete evaporation of methanol. The encapsulated drug particles were 
recovered by centrifugation (15,000 rpm, 20 min,4⁰C) using sorvall ultracentrifuge and the precipitate washed repeatedly 
three times with ice cold MilliQ water to ensure complete removal of polyvinyl alcohol. As a final point the product was 
dispersed in cold water and recovered by lyophilisation. Formulations T1-T9 were prepared keeping OP to AP ratio (1:5) 
and varying drug:polymer ratios given in Table 1. The unencapsulated drug presence were determined by measuring its 
absorbance at 278nm (SS), 257nm (AH), 351nm (MS).  
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Table 1. Formulation of microparticles 
Trial 
Code 
Drug:Polymer (1:1) Weight 
of  
Drugs 
(mg) 
Weight 
of 
polymer 
(mg) 
Vol. of 
DCM 
(ml)- OP 
AP Vol. (2% 
PVA) (ml)- 
AP 
% yield 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
SS:PLGA(50:50) 
SS:PLGA(75:25) 
SS:Eudragit RS100 
AH: PLGA(50:50) 
AH: PLGA(75:25) 
AH: Eudragit RS100 
MS: PLGA(50:50) 
MS: PLGA(75:25) 
MS: Eudragit RS100 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
5 
5 
5 
5 
5 
5 
5 
5 
5 
25 
25 
25 
25 
25 
25 
25 
25 
25 
82.25±1.38 
80.12±1.01 
75.21±1.72 
77.42±1.82 
75.92±1.01 
74.82±1.62 
77.10±1.08 
75.04±1.01 
73.51±1.62 
 
2.2 Preparation of dry powder for oral inhalation:  
 The prepared microparticles blended with inhalable grade lactose (lactohale) to enhance aerosol characters 
during inhalation [16-20]. This powder filled in to the size three hard empty gelatin capsules. 
2.3 Fourier Transform Infrared Spectroscopy (FTIR): 
 Infrared spectrum produces fingerprint and characterization of the SS, AH and MS to indentify functional groups 
of the molecules. The band intensities are proportional to the concentration of the compounds. Infrared spectroscopy was 
used to determine various functional groups of the drug molecule.  
2.4 Scanning Electron Microscopy (SEM): 
 The diameter, structural and surface morphology of prepared encapsulated particles were obtained through 
scanning electron microscope. The scanning electron microscopy (VEGA3) with maximum magnification 1 000 000*X and 
a resolution 3 nm at a voltage of 30 kV were used and investigated surface morphology and shape of the prepared 
microparticles. The specimens were examined with maximum vacuum and with accelerating voltage of 5-15 KV [21-24]. 
2.5 Entrapment Efficiency: 
 Drugs were extracted from the microparticles with 0.1M sodium hydroxide after dissolving it in acetonitrile. After 
suitable dilutions, the drug content was measured in a UV-Vis spectrophotometer (Jasco) at 278nm (SS), 257nm (AH), 
351nm (MS). Entrapment efficiency was calculated using the following formula: 
Entrapment efficiency was calculated using the following formula: 
Entrapment efficiency =  Estimated % drug content   X 100 
                       % drug content (theoretical) 
Percentage Yield: 
The percentage yield was calculated by using the following formula. 
Percentage yield = Actual wt. of microspheres × 100 
                  Wt. of starting materials 
2.6 Particle size evaluation by laser diffraction: 
 The particle sizes of microparicles were estimated by laser diffraction method. The Helos particle size 
determination with Sympatec GMbh systems were used for estimation of particle size. The dry powder 100mg was used to 
achieve the required obscuration of 5%. The particle size data obtained were represented as D0.5. 
2.7 In vitro deposition studies: 
 The anderson cascade impactor dealings particle size in accord with pharmacopoeia specifications [25-26]. The 
eight stages of Andersen Cascade Impactor (ACI) used for measuring the aerodynamic particle size distribution generated 
by dry powder inhaler such as rotahaler. The samples were collected on the surface of the collection plates, the middle was 
the preseparator connect with the glass expansion chamber and the right were the sieves, which filter the particles 
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according to their size [27-31]. The collection plates were layered with silicone oil to prevents bouncing of the particles while 
performing the studies. The outlet of the ACI is connected to a critical flow controller to create flow during testing. The 
airflow was 60 L/min. The ACI operation conditions were specified in Table 2. 
Table 2. Operating conditions and theoretical cut-off diameters of ACI 
ACI Parameters ACI Results 
Flow rate (L/min) 
Time per actuation (s) 
Volume per actuation (L) 
Cut off diameter (µm) 
Stage 0 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
Stage 5 
Stage 6 
Stage 7 
Stage 8 
60 
4 
4 
 
5.7 
4.5 
3.4 
2.3 
1.4 
0.8 
0.40 
0.12 
Filter 
2.8 In vitro drug release: 
 The dialysis bag dispersion technique used to calculate in vitro release of SS, AH and MS from the 
microparticles [32-36]. The diffusion medium phosphate buffer saline (PBS) pH 7.4 and a dialysis membrane of 14 kDa 
molecular weight (Himedia, Mumbai, India) were used. An aqueous dispersion of 10mg of drugs kept in a dialysis bag and 
sealed at both ends. The dialysis bag was immersed in 250 ml of diffusion medium (sodium phosphate buffer, pH 7.4 at 
37̊̊̊̊   
 
⁰C) and stirred at 100 rpm. Samples were withdrawn at predetermined time intervals, and the receptor phase was 
replenished with same volume of phosphate buffer saline after each sample was withdrawn. Samples were filtered through 
0.46 µm filter and appropriately diluted with pH 7.4 phosphate buffer saline. Absorbance of the samples was determined by 
UV/Vis spectrophotometry with pH 7.4 phosphate buffer saline as blank. The cumulative percent drug at various time 
intervals was determined and plotted against time. All experiments were done in triplicate. 
2.9 Filter paper disc diffusion method: 
The disc diffusion method was used to evaluate antibacterial and antifungal activity.  The test samples were prepared with 
the solvent dimethyl formamide. The 6 mm diameter sterile paper disc impregnated with extracted test samples of 
microparticles deposited on the surface of agar medium. The standard used was the ciprofloxacin (100mcg/ml) to study 
actimicrobial activity of microparticles prepared. The filter paper disc diffusion method was used to test by employing 24 
hours cultures of the respective microorganisms. The sterile nutrient agar used as medium and test organisms were 
seeded by homogenously mixing 1ml of inoculums with 20 ml sterile melted nutrient agar colled at 50⁰C in a  sterile 
petridish to get solidified. All the test samples and standard were impregnated in whatman filter paper disc and kept above 
the medium in the petridish and petridish kept undisturbed for 2 hours at room temperature. The petridish were incubated 
for 24 hours at 37⁰C and inhibition zone (mm) was measured. Antibacterial efficiency at different concentration (250 mcg/ml, 
500 mcg/ml, 1 mg/ml) were determined by using the filter paper disc diffusion method. The null bacterial growth of minimum 
dimension of the zone around the filter paper disc was measured and calculated the zone of inhibition. 
2.10 Method of MTT assay process 
  The alveolar epithelial cancer cell line A549 was used in the cell viability assay. The MTT reagent (3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) used to know cell viability. 500-10,000 cells were plated in a 96 
well plate by Leaving the 8th wells empty for controls. The seeded cells where incubated (37 °C, 5% CO2) overnight to 
allow the cells to attach to the wells. 2μl (depends on the concentration) of drug of interest dissolved in DMSO to each well. 
Placed on a shaking table, 150 rpm for 5 min, to thoroughly mix the samples into the media.  Incubated (37 °C, 5% CO2) 
for 1-5 days to allow the drug/toxin to take effect.  20μl MTT(5mg/ml in DMSO) solution added to each well and placed on 
a shaking table, 150 rpm for 5 min, to thoroughly mix the MTT into the media. Plates are incubated (37 °C, 5% CO2) for 1-5 
h to allow the MTT to be metabolized. Dump off the media and Resuspend formazan (MTT metabolic product) in 150μl 
DMSO with shaking table, 150 rpm for 5 min, to thoroughly mix the formazan into the solvent. The process detail presented 
in Table 3. Read optical density at 560 nm and subtract background at 660 nm.  
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Table 3. MTT assay process 
3. RESULT AND DISCUSSION 
 In the present study, microparticles were prepared by modified solvent evaporation method. The drugs were 
encapsuled with polymers in aqueous:organic phase. Encapsulation process involves vibracell sonication, homogenization, 
centrifugation and then freeze drying to yield microparticles [37-41]. Kept organic aqueous solution ratio as 1:5 (30 ml of 
organic:aqueous solution as 5:25ml respectively mixed with 1:1 drug polymer ratio). Presence of polymer ensures good 
yield of microparticles [42-43]. 
Particle size analysis, entrapment efficiency of microparticles, weight variation and 
drug content of DPI: 
 The particle size, and entrapment efficiency were evaluated for microparticles and demonstrated in Table 4.  
The size distribution of microparticles (laser diffraction) was observed for formulations T1-T9. The mean particle size of 
microparticles of formulation T1, was better than other formulation T2-T9. Entrapment efficiency for formulations with PLGA 
(50:50) were better than PLGA (75:25) and Eudragit RS100. The Table 5 described on the weight variation and drug 
content of capsule contains homogenous mixture of Drug:lactohale (1:19) of formulations T1-T9. The average weight of 
filled capsules was 20 mg containing 1 mg of drugs (SS, AH and MS). In all formulation measurement, the uniformity of 
weight and drug content in the capsule was achieved.  
Table 4. Particle size, entrapment efficiency of microparticles 
Trial Code Particle size (D0.5 nm)   
Mean ±SD 
Entrapment         
efficiency 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
1.94±0.6 
1.92±0.2 
1.82±0.8 
1.93±0.5 
1.91±0.3 
1.88±0.6 
1.91±0.1 
1.90±0.5 
1.86±0.7 
76.62±0.32 
73.12±0.41 
71.16±0.54 
75.14±0.21 
74.24±0.12 
72.17±0.15 
72.12±0.36 
70.06±0.47 
69.09±0.26 
Table 5. Weight variation and drug content of dry powder inhaler 
Trial Code Weight Variation 
(mg ± SD) 
 
Drug Content 
(%) 
S. 
No 
Reagents Test Sample (T1-T9) Blank (B) 
 
T1 T2 T3 T4 T5 T6 T7 T8 T9 B 
1 Cell culture 100 
µl 
100 
µl 
100 
µl 
100 
µl 
100 
µl 
100 
µl 
100 
µl 
100 µl 100 
µl 
- 
 Incubate at 37° C for Over night 
2 MTT 
Reagent 
10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 10  
µl 
10 µl 
3 PBS - - - - - - - - - 100 µl 
 Incubate at 37° C  for 2-4 hrs 
4 DMSO 150µ
l 
150µ
l 
150µ
l 
150 
µl 
150µ
l 
150µ
l 
150µ
l 
150 µl 150µ
l 
150µl  
 Incubate at 37° C for 15mins in dark 
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T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
20.06±0.05 
20.11±0.12 
19.94±0.20 
20.09±0.08 
20.21±0.22 
19.93±0.23 
20.09±0.08 
20.01±0.10 
19.93±0.20 
99.2-100.5 
99.0-101.4 
98.9-102.5 
99.1-100.8 
99.0-100.2 
98.5-102.0 
98.1-100.2 
99.7-101.2 
98.4-100.9 
 
Drugs compatibility in formulations by FTIR spectra: 
 The interaction of drugs in formulations T1-T9 were evaluated in Fourier transform infrared spectroscopy 
(FTIR-Perkin Elmer of scanning range 450-4000 cm
-1
) was presented in Fig. 1-12. Spectral graphs were given as wave 
number (cm
-1
) against Transmittance (%). SS produces sharp bands at wavelength of about 1000 cm
-1
, as spectra of 
formulation also show bands at same wavelength, but somewhat less intense. AH shows peaks at 3350, 3400, 1590, 1540 
and 700 cm
-1
 [44-45]. The peak of AH at 3400, 3345 and 1074 cm
-1
 becomes relatively narrow, which could be attributed to 
the stretching vibration of phenolic hydroxyls (OH bond), and confirms the interactions of phenolic hydroxyl groups [46]. MS 
exhibits many aromatic CH peaks observed from 2900cm
-1
 to 3000cm
-1.
 There is no difference in the positions of 
absorption bands was observed in the spectra of drugs (SS, AH and MS) and formulation trials T1-T9, demonstrating no 
chemical interaction between drugs and polymer in solid state. From the observation drugs were found to be stable in 
formulation trials T1-T9. 
 
Fig. 1. FTIR graph of salbutamol sulphate 
 
 
Fig. 2. FTIR graph of formulation trial T1 
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Fig. 3. FTIR graph of formulation trial T2 
 
Fig. 4. FTIR graph of formulation trial T3 
 
Fig. 5. FTIR graph of ambroxol hydrochloride 
 
Fig. 6. FTIR graph of formulation trial T4 
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Fig. 7. FTIR graph of formulation trial T5 
 
Fig. 8. FTIR graph of formulation trial T6 
 
 
Fig. 9. FTIR graph of montelukast sodium 
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Fig. 10. FTIR graph of formulation trial T7 
 
Fig. 11. FTIR graph of formulation trial T8 
 
 
Fig. 12. FTIR graph of formulation trial T9 
Scanning electron microscopy: 
 Scanning electron microscope (SEM-VEGA3) analysis showed the surface morphology of microparticles Fig. 
13-21. The scanning range was 400-4000 cm
-1
 and the resolution was 2/cm. The SEM image showed microparticles are 
nearly spherical in nature.  
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Fig. 13. SEM photograph of formulation T1 
 
Fig. 14. SEM photograph of formulation T2 
 
Fig. 15. SEM photograph of formulation T3 
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Fig. 16. SEM photograph of formulation T4 
 
Fig. 17. SEM photograph of formulation T5 
 
 
Fig. 18. SEM photograph of formulation T6 
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Fig. 19. SEM photograph of formulation T7 
 
Fig. 20. SEM photograph of formulation T8 
 
Fig. 21. SEM photograph of formulation T9 
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Anderson cascade impaction studies: 
The In vitro depositions of powder particles in the lung were evaluated by powder particle distribution in the stages of 
Anderson cascade impactor (ACI, Copley Scientific)[47]. The distribution of powder particles were graphically 
demonstrated in Fig. 22-30, showing mean (SD) percent emitted dose deposited on each stage of the ACI using Rotahaler 
at 60 L min
-1
 (n = 6). The respiratory fraction[48-49]
 
(particle deposition in stage 2-8) and mass median aerodynamic 
diameter of formulation T1-T3 were given in Table 6, T4-T6 were given in Table 7 and T7-T9 were given in Table 8.  
 
 
 
 
Fig. 22. ACI for % deposition profiles in each stage for formulation T1 
 
 
 
Fig. 23. ACI for % deposition profiles in each stage for formulation T2 
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Fig. 24. ACI for % deposition profiles in each stage for formulation T3 
 
 
 
Fig. 25. ACI for % deposition profiles in each stage for formulation T4 
 
 
Fig. 26. ACI for % deposition profiles in each stage for formulation T5 
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Fig. 27. ACI for % deposition profiles in each stage for formulation T6 
 
Fig. 28. ACI for % deposition profiles in each stage for formulation T7 
 
 
Fig. 29. ACI for % deposition profiles in each stage for formulation T8 
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Fig. 30. ACI for % deposition profiles in each stage for formulation T9 
Table 6. ACI results for the formulations T1, T2 and T3 measured using an air-flow rate of 60 
L min
-1
 (n = 6). 
Particle size Attributes ACI (inhalation indices) Mean ± SD 
T1 T2 T3 
Emitted dose (%) 98.8 ± 2.57 98.2 ± 2.97 98.2 ± 2.96 
Respiratory fraction
 
(%) 34.9 ± 2.59 33.7± 3.08 33.1 ± 2.93 
Total recovery 99.8 ± 3.02 98.9 ± 3.37 98.9 ± 2.96 
Mean median aerodynamic diameter (μm) 1.75 ± 0.11 1.94 ± 0.12 2.14 ± 0.21 
 
Table 7. ACI results for the formulations T4, T5 and T6 measured using an air-flow rate of 60 L min
-1
 (n = 6). 
Particle size Attributes ACI (inhalation indices) Mean ± SD 
       T4         T5        T6 
Emitted dose (%) 98.5± 2.39 96.8 ± 2.8 96.9 ± 2.87 
Respiratory fraction
 
(%) 34.5 ± 2.17 32.2± 2.8 31.9 ± 2.70 
Total recovery 99.5 ± 2.82 97.8 ± 3.1 97.9 ± 3.16 
Mean median aerodynamic diameter (μm) 1.72 ± 0.3 1.90 ± 0.20 2.24 ± 0.01 
 
Table 8. ACI results for the formulations T7, T8 and T9 measured using an air-flow rate of 60 L min
-1
 (n = 6). 
Particle size Attributes ACI (inhalation indices) Mean ± SD 
T7 T8 T9 
Emitted dose (%) 97.6± 3.09 97.9 ± 3.1 97.2 ± 3.04 
Respiratory fraction
 
(%) 33.8 ± 2.84 32.4± 2.65 31.2 ± 2.67 
Total recovery 98.6 ± 3.47 98.9 ± 3.45 98.2 ± 3.38 
Mean median aerodynamic diameter (μm) 1.71 ± 0.10 1.89 ± 0.3 2.14 ± 0.11 
The in vitro drug dissolution: 
 The dissolution was carried out in PBS at pH 7.4 at 37°±0.5°C. The drug released at 12 h of formulation trials 
were T1, 91.23 %; T2, 86.92%; T3, 85.05 %; T4, 90.67; T5, 85.27%; T6, 84.05; T7,90.56; T8,86.91 and T9,83.67. The drug 
releases were found to be not less than 80% at 12 h in all trials. The Fig. 31-33 represents cumulative percent drug release 
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versus time in hours for formulations T1-T9. It was understood that the drug release versus time proved the sustained 
release of drugs in all formulations T1-T9. SS:PLGA(50:50) Formulation T1 exhibited best dissolution result, when 
compared to other formulations T2-T9 [50].  
 
Fig. 31. Cumulative Percent drug release versus time (h) for formulations T1-T3 (n=3). 
 
 
Fig. 32. Cumulative Percent drug release versus time (h) for formulations T4-T6 (n=3). 
 
Fig. 33. Cumulative Percent drug release versus time (h) for formulation trials T7-T9 (n=3). 
Antibacterial activity: 
The antibacterial activity of the dry powder inhaler formulation trials T1-T9 were studied against gram positive, gram 
negative bacteria and fungi shown in Table 9. The three respiratory drugs were found demonstrated antibacterial activity. 
The minimum inhibitory concentrations were determined. Significant antimicrobial activity was found with the dry powder 
inhaler formulation. The microparticle possess a notable antibacterial action against all the microorganisms were tested.  
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Table 9. Minimum inhibitory (mm) concentration of the microorganism for Trial T1 – T9 
Test Micro organisms Zone of inhibition (mm) 
Sample 250 µg/ml 500 µg/ml 1mg/ml Standard* 
Staphylococcus aureus 
(Gram positive) 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
5 
6 
6 
6 
5 
6 
7 
6 
7 
7 
6 
6 
8 
6 
7 
7 
8 
7 
10 
10 
9 
10 
10 
8 
9 
8 
8 
19 
18 
17 
20 
19 
20 
21 
20 
20 
Micrococcus luteus 
(Gram positive) 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
7 
6 
6 
5 
5 
5 
6 
6 
6 
8 
7 
6 
9 
8 
7 
7 
6 
6 
11 
10 
9 
10 
11 
10 
10 
9 
10 
20 
20 
19 
21 
19 
20 
19 
18 
17 
Escherichia coli (Gram 
negative) 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
6 
6 
5 
7 
6 
6 
5 
4 
5 
9 
7 
8 
8 
7 
7 
7 
8 
7 
10 
10 
9 
9 
8 
9 
11 
10 
10 
20 
20 
19 
21 
20 
19 
20 
19 
20 
Pseudomonas 
aeruginosa (Gram 
negative) 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
6 
5 
5 
6 
5 
6 
7 
6 
7 
9 
7 
7 
8 
8 
7 
8 
6 
7 
9 
9 
8 
10 
9 
10 
11 
10 
10 
21 
20 
20 
20 
19 
19 
19 
18 
18 
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Aspergillus niger (Fungi) T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
7 
7 
6 
5 
5 
4 
6 
5 
4 
7 
7 
6 
8 
7 
7 
7 
6 
6 
10 
9 
10 
9 
9 
9 
11 
10 
11 
20 
20 
19 
19 
18 
18 
20 
19 
19 
*Standard - ciprofloxacin 
MTT assay: 
The sustained release microparticles tested for by cell line studies. The Invitro cell viability assayed (MTT assay) carried out 
by alveolar epithelial cancer cell line A549 for formulations T1-T9. MTT assay is a colorimetric method for measuring the 
activity of enzymes in living cells that reduce MTT to formazan dyes, giving a purple color. The process of MTT assay given 
in table 8. It is commonly used to determine cytotoxicity of potential medicinal agents and toxic materials, since these types 
of materials are expected to stimulate or inhibit cell viability and growth. At 500 𝜇g concentration, formulations T1-T9 showed 
more than 80% cell viability. The results indicated that the formulations are safe proved with alveolar epithelial cancer cell 
line A549 by invitro cell viability assay. Percentage of cell viability graph of T1-T9 was presented in Fig. 34. 
Calculated the cell density and percentage cell viability using the following formula 
 
Calculated the average cell density of triplicates: 
                                     
    Optical density of sample       
Percentage of cell viability (%)   =                               X 100  
                                      Optical density of Control 
 
 
Fig. 34. Percentage cell viability against alveolar epithelial cancer cell line A549 of formulated DPI; Data are 
presented as mean ± SD, 𝑛 = 3. 
CONCLUSION 
The orally inhalable dry powder formulation was prepared using drug and polymers for encapsulation. The prepared 
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microparticles committed for sustained drug delivery in airways through inhalation. All the formulations had extended in 
vitro drug release profile upto 12 hours. Formulation T1 compared with all the nine formulations based on laboratory 
analysis was best. In vitro drug deposition studies exhibit optimum characteristics of respirable particles. Further invivo 
studies will be carried out to analyse clinical characteristics of formulations. 
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